Physician profile
Nima Aghdam
NPI 1942696752
$28,785.21
in general payments reported to CMS, 2019-2025
8 companies · $16K in 2025
The $16K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4,682 · 2024: $8,347 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Honoraria: $1,500 · Travel and Lodging: $1,373 · Food and Beverage: $1,313 · Education: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,300.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,373.08 |
| Food and Beverage | $1,313.13 |
| Education | $1,299.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accuray Incorporated | $18,956.97 | 2023-2025 | Cyberknife System, Tomo Therapy System |
| Bioprotect Medical, INC. | $9,172.09 | 2024-2025 | Bioprotect Balloon Implant System |
| Blue Earth Diagnostics | $444.98 | 2024-2025 | Posluma |
| Novartis Pharmaceuticals Corporation | $104.19 | 2025 | |
| Teleflex LLC | $29.94 | 2025 | Barrigel |
| Pfizer INC. | $27.01 | 2025 | |
| Sumitomo Pharma America, INC. | $25.05 | 2025 | Orgovyx |
| Astrazeneca Pharmaceuticals Lp | $24.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Aghdam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.